FDA’s program to spur the development of antibiotics for tough-to-treat bacterial infections scored its first point with the approval of Durata Therapeutics Inc.’s antibiotic Dalvance (dalbavancin) on May 23, and the commercialization will be an important test of the significance of the incentive program.
The drug was one of the first products to receive the agency’s Qualified Infectious Disease Product designation (QIDP), which was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?